These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 1986099)

  • 61. Hepatic hemangiomas in infants and children: a review of 30 cases.
    Iyer CP; Stanley P; Mahour GH
    Am Surg; 1996 May; 62(5):356-60. PubMed ID: 8615561
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Mediastinal Kaposiform hemangioendothelioma and Kasabach-Merritt phenomenon in an infant: treatment with interferon.
    Hartman KR; Moncur JT; Minniti CP; Creamer KM
    J Pediatr Hematol Oncol; 2009 Sep; 31(9):690-2. PubMed ID: 19687760
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Chronic disseminated intravascular coagulation (DIC) markers in a patient with multiple angiomatosis during treatment with anti-angiogenics: interferon α, thalidomide and lenalidomide].
    Adam Z; Pour L; Matýšková M; Krejčí M; Tomíška M; Szturz P; Rehák Z; Koukalová R; Křikavová L; Nebeský T; Neuman C; Navrátil M; Hájek R; Král Z; Mayer J
    Vnitr Lek; 2012 Feb; 58(2):145-53. PubMed ID: 22463096
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Therapeutic efficacy of interferon alfa-2b in infants with life-threatening giant hemangiomas.
    Tamayo L; Ortiz DM; Orozco-Covarrubias L; Durán-McKinster C; Mora MA; Avila E; Teixeira F; Ruiz-Maldonado R
    Arch Dermatol; 1997 Dec; 133(12):1567-71. PubMed ID: 9420543
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behçet uveitis.
    Onal S; Kazokoglu H; Koc A; Akman M; Bavbek T; Direskeneli H; Yavuz S
    Arch Ophthalmol; 2011 Mar; 129(3):288-94. PubMed ID: 21402983
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Long-term versus short-term treatment with recombinant interferon alfa-2a in patients with chronic hepatitis B: a prospective, randomized treatment trial.
    Rakela J; Wood JR; Czaja AJ; O'Brien PC; Taswell HF; Bowyer BA; Lange SM; Anderson ML; Parent K
    Mayo Clin Proc; 1990 Oct; 65(10):1330-5. PubMed ID: 2214880
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Malignant hemangiosarcoma in a renal allograft: diagnostic difficulties and clinical course after nephrectomy and immunostimulation.
    Kuntzen D; Tufail Hanel M; Kuntzen T; Yurtsever H; Tuma J; Hopfer H; Springer O; Bock A
    Transpl Int; 2014 Aug; 27(8):e70-5. PubMed ID: 24617294
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Caution with regard to the efficacy of interferon alfa-2b in the treatment of giant hemangiomas.
    Léauté-Labrèze C; Taïeb A
    Arch Dermatol; 1998 Oct; 134(10):1297-8. PubMed ID: 9801696
    [No Abstract]   [Full Text] [Related]  

  • 69. Additional corrections: interferon for hemangiomas of infancy.
    Ezekowitz A; Mulliken J; Folkman J
    N Engl J Med; 1995 Aug; 333(9):595-6. PubMed ID: 7623913
    [No Abstract]   [Full Text] [Related]  

  • 70. Central nervous system hemangiomatosis in early childhood.
    Capin DM; Gottlieb SM; Rosman NP
    Pediatr Neurol; 1997 Nov; 17(4):365-70. PubMed ID: 9436805
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Interferon alfa-2a in the treatment of subfoveal choroidal neovascularization.
    Thomas MA; Ibanez HE
    Am J Ophthalmol; 1993 May; 115(5):563-8. PubMed ID: 7683842
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
    Lau GK; Piratvisuth T; Luo KX; Marcellin P; Thongsawat S; Cooksley G; Gane E; Fried MW; Chow WC; Paik SW; Chang WY; Berg T; Flisiak R; McCloud P; Pluck N;
    N Engl J Med; 2005 Jun; 352(26):2682-95. PubMed ID: 15987917
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Recurrent hemoptysis as initial symptom of a thoracic angiomatosis in an adult patient].
    Bastian D; Mödl B; Nentwich K; Engel G; Brunner E; Holper K
    Pneumologie; 2002 Nov; 56(11):689-94. PubMed ID: 12442210
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Symptomatic Congenital Hemangioma and Congenital Hemangiomatosis Associated With a Somatic Activating Mutation in GNA11.
    Funk T; Lim Y; Kulungowski AM; Prok L; Crombleholme TM; Choate K; Bruckner AL
    JAMA Dermatol; 2016 Sep; 152(9):1015-20. PubMed ID: 27438697
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Combination of "low-dose" ribavirin and interferon alfa-2a therapy followed by interferon alfa-2a monotherapy in chronic HCV-infected non-responders and relapsers after interferon alfa-2a monotherapy.
    Wietzkebetaraun P; Meier V; Braun F; Ramadori G
    World J Gastroenterol; 2001 Apr; 7(2):222-7. PubMed ID: 11819764
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Kasabach-Merritt syndrome of the leg associated with osteolysis or Gorham sign].
    Kerhoas Nicolas CK; Le Bidaut M; Dosquet C; Enjolras O; Stalder JF
    Ann Dermatol Venereol; 1997; 124(12):852-4. PubMed ID: 9732759
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
    Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
    N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma.
    Escudier B; Szczylik C; Hutson TE; Demkow T; Staehler M; Rolland F; Negrier S; Laferriere N; Scheuring UJ; Cella D; Shah S; Bukowski RM
    J Clin Oncol; 2009 Mar; 27(8):1280-9. PubMed ID: 19171708
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Response of deep tufted angioma to interferon alfa.
    Suarez SM; Pensler JM; Paller AS
    J Am Acad Dermatol; 1995 Jul; 33(1):124-6. PubMed ID: 7601929
    [No Abstract]   [Full Text] [Related]  

  • 80. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
    Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
    J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.